All News
Mortality in Low Dose Prednisone
Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.
Read Article
RheumNow Podcast – Back Talk Listener Questions (12.04.20)
Dr Jack Cush takes questions from RheumNow listeners
Read Article
Taiwanese claims data on new RA (2003‐2016) shows decreasing incidence over time. After RA Dx the life expectancy was 26.3 yrs; lifetime cost US$ 72,953. On avg RA pts live 4.97 years less (historically this was 8-11yrs); has biologic era improved this? https://t.co/gHbZx1bw0A
Links:
Dr. John Cush RheumNow ( View Tweet)
Hepatitis B, RA and Drug Risk with Drs. Stanley Cohen and Jack Cush #ACR20
https://t.co/jOzAkLzNEc https://t.co/lPM8bbHDr7
Links:
Dr. John Cush RheumNow ( View Tweet)
1st refractory to DMARD can be bad omen. RA Study showed 41/402 (10%) were multi-DMARD refractory (MR) and 18% achieved remission/LDAS. DMARD MR predicted by erosions, younger age, high baseline DAS28, delta-DAS < 1.2 1st 6 mos (OR 11.12) https://t.co/KxdK97uuSI
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : Big wins for #pedirheum!
#FDA had approved for JIA;2 y.o:
9/29 golimumab iV for JIA/PsA
9/25 tofacitinib (weight based dosing) for polyarticular JIA (tofacitinib dosing for JIA: 10 kg-20kg: 3.2 mg bid, for 20-40 kg 4 mg bid, for 40 kg 5 mg bid)
Dr. John Cush RheumNow ( View Tweet)
ABCs of RA: Panel Discussion with Dr. Jonathan Kay #acr20
https://t.co/9HTTyPjCBV https://t.co/uDtS2EsMng
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway : Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/TR9IS9hUgu
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD : A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI; hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
"RT @drdavidliew : Just a reminder:
inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced.
@LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/x7DLzZcn9o https://t.co/OmpTAorA13
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD : Wonder if you can predict which pts you can taper off bDMARDs? Abst#1538 from Denmark showed that a neg IgM-RF (OR 0.26); low Doppler serum score for 24 jts predicted discontinuation of bDMARDs at 2yr f/u in RA pts w/ DAS28-CRP<2.6. https://t.co/6hv5M1CQwT
Dr. John Cush RheumNow ( View Tweet)
Coal Miners and RA: Dr Janet Pope ( @Janetbirdope) reviews abstract #1462 presented at #ACR20.
https://t.co/frZ3uYNsuA https://t.co/nFHmzYA8KS
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/HUucJOgQgN https://t.co/xJB2zU1y2U
Links:
Dr. John Cush RheumNow ( View Tweet)
The Lungs: The Alpha and Omega of RA with Dr. Jonathan Kay #ACR20
https://t.co/zhCRaeKOfu https://t.co/zVwgzu9ULs
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: Use MTX, starting oral but remember MTX tricks to maximize success. Folic acid, split dosing, SubQ all keys per Dr. O'Dell to maximize @RheumNow. https://t.co/OEAGi0bSZH https://t.co/aHsHF1Vm4l
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: on max tolerated MTX - add bio or tsDMARD conditional recommendation over triple therapy (MTX, HCQ, SSZ). @RheumNow. https://t.co/uff7Vj0iKA https://t.co/Tquq7FN86y
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: discontinue MTX over biologic or tsDMARD in "patients that strongly want to discontinue", conditional recommendation supported by SEAM-RA Abst#939 @RheumNow https://t.co/2Ozvkq4Rjo https://t.co/xlbKAItFzN
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out our latest article from Dr. Janet Pope ( @Janetbirdope)
How are RA patients doing using telemedicine/virtual care?
https://t.co/YffT28OwgY https://t.co/xnAe3lKL8W
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD :Conditional recommendation to add bDMARD or tsDMARD in RA pts on maximally tolerated dose of MTX over adding HCQ+SSZ (triple therapy) per draft recommendation of new ACR RA treatment guidelines. #ACR20 @ElaineHusniMD https://t.co/tCAbgYi3h0 https://t.co/AoEOJd3pQh
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Draft #ACR20 Rx Recs for RA: Treatment recommendations for Hepatitis B - highest risk is for RTX for reactivation! @RheumNow. https://t.co/JvYm9Ii6PV https://t.co/qjXBuzUug6
Links:
Dr. John Cush RheumNow ( View Tweet)
